Sodium retention in rats with liver cirrhosis is associated with increased renal abundance of NaCl cotransporter (NCC)

Zhenrong Yu1, Andreas Serra1, Daniel Sauter2, Johannes Loffing2, Daniel Ackermann1, Felix J. Frey1, Brigitte M. Frey1 and Bruno Vogt1

1Division of Nephrology and Hypertension, University Hospital Inselspital, Berne, Switzerland and 2Institute of Anatomy, University of Zürich, Zürich, Switzerland

Abstract
Background. Liver cirrhosis is associated with enhanced renal tubular sodium retention, the mechanism of which is still debated. We hypothesized that liver cirrhosis is associated with increased expression of renal epithelial sodium transporter(s).

Methods. Liver cirrhosis was induced by bile duct ligation (BDL) in rats. Steady state mRNA of ENaC subunits α, β, γ and serum glucocorticoid inducible kinase (Sgk1) were measured by TaqMan PCR in kidney homogenates at week 1, 2, 3 and 4 after BDL. Renal protein content of ENaC subunits, ubiquitin-protein-ligase Nedd4-2 and NaCl cotransporter (NCC) were assessed by western blot. Subcellular localization of ENaC subunits and NCC were analysed by immunohistochemistry.

Results. Steady state mRNA of ENaC α, β and γ were unchanged during the 4 weeks investigated, while ENaC protein decreased most prominently at week 2 (control vs BDL: α, −46%; β, −81%; and γ, −63%; n = 6). Subcellular localization of ENaC subunits was not altered at week 2. Sgk1 mRNA did not change, whereas Nedd4-2 protein was reduced by >50% 2–4 weeks after BDL. NCC protein significantly increased at week 1 (control vs BDL: +66%, n = 6, P < 0.05) and decreased at week 3 (control vs BDL: −85%, n = 6, P < 0.0005).

Conclusions. Enhanced abundance of NCC was observed in the initial stage after BDL, followed by a marked decrease. ENaC transcription, translation or cell surface abundance was not increased after BDL.

Keywords: epithelial sodium channel (ENaC); bile duct ligation (BDL); liver cirrhosis; Na-Cl cotransporter (NCC); Nedd4-2; serum glucocorticoid inducible kinase 1 (Sgk1)

Introduction

Regulation of renal sodium excretion is crucial for maintaining extracellular fluid (ECF) volume within normal limits. Any manoeuvre that increases ECF volume causes a prompt and sustained natriuresis until volume returns to normal. This homeostatic mechanism is disturbed in patients with liver cirrhosis; enhanced renal salt retention increases ECF volume, contributing to the formation of oedema and ascites.

The aldosterone sensitive distal tubule (ASDN) of the kidney, comprising at least the late part of the distal convoluted tubule (DCT), the connecting tubule (CNT) and the cortical as well as the medullary collecting duct (CCD and MCD, respectively) is central for the regulation of ECF volume in many disease states [2]. With respect to liver cirrhosis, several lines of evidence suggest that the ASDN is the key segment involved in enhanced renal sodium retention and potassium loss. For example, it is well established in clinical practice that the mineralocorticoid receptor antagonist spironolactone with its primary action in the ASDN restores ECF volume in patients with liver cirrhosis [3]. From experimental studies it has become clear that various mechanisms explaining enhanced renal avidity of sodium in the cirrhotic disease state are most likely located in the ASDN. Increased concentrations of ligands accounting for enhanced mineralocorticoid receptor (MR) activation in CCD in liver cirrhosis have been reported. In some animal models and humans with cirrhosis, aldosterone levels were found to be increased and/or the access of cortisol to the MR enhanced, due to a bile acid-mediated...
inhibition of the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), the gate-keeper enzyme for MR activation by the glucocorticoid cortisol [4–6]. Taken together, these findings suggest that renal tubular mechanisms are responsible for sodium retention, which mainly occur at the ASDN, the site of action of mineralocorticoid hormones.

The rate-limiting factor of vectorial sodium transport induced by MR-activating ligands in the ASDN is the induction of the amiloride-sensitive sodium channel (ENaC) [2]. This channel is composed of homologous 2α, 1β and 1γ subunits. Serum glucocorticoid-inducible kinase (Sgk1) causes an increase in ENaC channels at the cell surface, is induced by aldosterone and appears to be a primary mediator of aldosterone action. ENaC clearance at the cell surface is regulated by ubiquitylation mainly through the ubiquitin-protein ligase Nedd4-2, a negative regulator of ENaC. Sgk1 phosphorylates Nedd4-2 and by this mechanism impairs the interaction between Nedd4-2 and ENaC, leading to elevated ENaC cell surface expression and increased sodium absorption [7].

The thiazide-sensitive NaCl cotransporter (NCC), which is expressed on the apical membrane of epithelial cells lining the distal convoluted tubule, is responsible for the reabsorption of at least 3% of the filtered load of sodium. Evidence for a regulatory action of the mineralocorticoid hormone aldosterone on NCC comes from several observations in whole-animal studies [8]. Enhanced MR activation might increase NCC expression and/or NCC sensitive sodium uptake and contribute to renal sodium retention in liver cirrhosis. The aim of the present study was to investigate the impact of liver cirrhosis induced by bile duct ligation on the renal expression of ENaC, on the ENaC regulating proteins, and on NCC.

Methods

Experimental animals

Male Sprague-Dawley rats (200–220 g body wt) were maintained on standard laboratory chow and tap water with a 12 h light/dark cycle at a constant temperature and humidity. The animal work was undertaken according to the Swiss national legislation governing the use of animals and the committee on animal research at the University of Berne. We used bile duct excision to produce cirrhosis as in previous investigations [4]. All bile duct ligated animals had coarsely granular livers and portal hypertension by macroscopic inspection. Animals were allotted to bile duct excision (n = 24) or sham surgery (n = 24). After an adaptation period of 7 days, animals were anaesthetized with ketamine (75 mg/kg body weight) and xylazine (5 mg/kg body weight) administered subcutaneously and a 2 cm upper abdominal midline incision was made. In the experimental group, the bile duct was isolated and a 0.5 cm section was excised after a double ligation. In the sham group, the bowel and mesentery bile duct was isolated and a 0.5 cm section was excised after a midline incision was made. In the experimental group, the

Metabolic studies and plasma aldosterone

Plasma aldosterone concentrations were determined by a radioimmunoassay (Iodine-125 tracer, Coat-A-Count; Diagnostic Products Corporation, Los Angeles CA). Serum and urine creatinine was determined on a Hitachi 917 autoanalyser (Roche, Basel, Switzerland) according to a modified Jaffé method. Creatinine clearance was calculated by the standard formula: $U_{\text{creat}} \times V_{\text{urine}} / P_{\text{creat}}$ (Ucreat, creatinine concentration in urine; $V_{\text{urine}}$, volume of urine in 24 h collection; $P_{\text{creat}}$, plasma concentration of creatinine).

RNA extraction

Kidneys were homogenized in RNA extraction buffer using a Polytron. Total RNA was extracted according to the method of Chomczynski and Sacchi with minor modifications: the RNA pellet resulting from the first precipitation was resuspended in DEPC-treated water, and 0.1 vol of 2 M sodium acetate and 1 vol of phenol pH 4.0 were added sequentially [10]. The suspension was vortexed, centrifuged at 10 000 g for 20 min, and the upper phase precipitated with isopropanol at −20°C for 1 h.

Reverse transcription

Reverse transcription (RT) was performed using 2 mg of total RNA in a final volume of 20 ml. RNA was incubated with 500 ng of oligo(dT) primer at 65°C for 5 min, followed by incubation at room temperature for 15 min. Samples were then incubated with 250 mM deoxynucleotide triphosphates, 20 U of RNase-Inhibitor, and 25 U of AMV reverse transcriptase (Roche, Rotkreuz, Switzerland) in 1× buffer (50 mM Tris–HCl, 40 mM MgCl2, 30 mM KCl, 1 mM DDT, pH 8.5) at 42°C for 1 h. For control reactions (RT–), enzymes were replaced by DEPC-treated-water.

Real-time PCR

Primers (Microsynth, Balgach, Switzerland) and TaqMan probes (Applied Biosystems, Rotkreuz, Switzerland) unique for each rat isoform were designed, optimized and validated: 5'-ctggccaatgtagcatcataaag (GAPDH); 3'-agccacagatgcttgtag (GAPDH); 5'-cagagttgtttctgtg (α-ENaC); 3'-ccagacagcaatgc (α-ENaC); 5'-catattcttagctgttgtag (β-ENaC); 3'-cattgcataagcgttagga (β-ENaC); 5'-tgaaagccactgtgcagtt (γ-ENaC); 3'-gaagagcctggct (γ-ENaC); 5'-aggagagcctggcttc (Sgk1); 3'-ccagacagcgttcatttc (Sgk1). These probes were used for GAPDH (tcggccgcctgcttcacca); α-ENaC (tgaagccacatcattaaagcaag); β-ENaC (ctcgtcagatcgaatgcagct); γ-ENaC (aatgcagacacacgctg); Sgk1 (cgctgctgttcactc); Real-time quantitative TaqMan PCR was performed by ABI PRISM 7700 Sequence Detection System. Diluted RT samples (10 ng of total RNA) were amplified in a final volume of 25 ml. Primers were used at a
concentration of 200 nM, probes (FAM/TAMRA labelled) at a concentration of 100 nM except for γENaC for which the probe concentration was 200 nM. GAPDH was used as a housekeeping gene and amplified in separate reactions. RT<sup>+</sup> reactions were performed in triplicate, RT<sup>-</sup> in duplicate. The thermal cycling conditions were as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.

**Western blots**

Sucrose buffer containing 250 mM sucrose, 1 mg/ml leupeptin (Sigma, St Louis, MO), 10 mM triethanolamine (Merck, Germany) and 0.1 mg/ml PMSF (Calbiochem, Germany), pH 7.6 was freshly prepared. Frozen powdered kidney tissue was homogenized in cold sucrose buffer using FastPROTEIN GREEN tubes (Lysing Matrix D, Q-Biogene, Alexis Corp, Lausanne, Switzerland) and a B101 Savant FastPrep FP120 device (Q-Biogene) at a speed of 4.0 U for 20 s. The homogenized tissue was centrifuged at 4°C, 3600 r.p.m., for 10 min. The supernatant was kept on ice and the pellet, dissolved in sucrose buffer, was centrifuged at the same speed again. The second supernatant was pooled with the first supernatant and the protein concentration determined using the BCA kit (Pierce BCA Protein Assay Reagent Kit, Pierce). From each sample 30 mg of protein was incubated with Lämmlti buffer at 37°C. From each sample 30 mg of protein was incubated with the BCA kit (Pierce BCA Protein Assay Reagent Kit, Pierce). From each sample 30 mg of protein was incubated with the BCA kit (Pierce BCA Protein Assay Reagent Kit, Pierce). From each sample 30 mg of protein was incubated with the BCA kit (Pierce BCA Protein Assay Reagent Kit, Pierce).

**Immunohistochemistry**

Kidney fixation and immunohistochemistry for ENaC were performed at weeks 1 and 2 as described [9]. For detection of ENaC, we used a set of newly generated rabbit anti-ENaC antibodies that were kindly provided by Dr B. Rossier, University of Lausanne, Switzerland. Serial cryosections were stained with the anti-rat αENaC antiserum diluted 1:1000, the anti-rat βENaC antiserum diluted 1/500, the anti-rat γENaC antiserum diluted 1/400, and the anti-rabbit NCC diluted 1/1000 antiserum. Binding sites of the primary antibodies were detected with Cy3-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA), diluted 1/1000 [13]. All antibodies were diluted in PBS/BSA 1%. For control of unspecific antibody binding, the primary antibodies were omitted or replaced by a non-immune rabbit serum. Immunostainings were evaluated by two investigators blinded for the treatment group of the animals. Both investigators came independently to the same conclusions concerning the subcellular localization and quantitatively assessed immunostaining intensities for the analysed proteins.

**Statistics**

Statistical analyses were performed with SYSTAT 10.0 for Windows (SPSS INC, Chicago, IL) for non-parametric data (Mann–Whitney). Two-way ANOVA was used to determine the effect of time and treatment with BDL on measured parameters. Results are presented as mean ± SD.

**Results**

**Metabolic studies and plasma aldosterone concentrations**

At week 1, jaundice was present in the BDL animals and at week 3 these animals showed clear signs of ascite formation. Body weight increased at week 4 when compared to the sham operated animals (Table 1). Sodium retention was observed at weeks 1 and 4 with no significant reduction in renal function (Table 2). Plasma aldosterone concentrations were unchanged in BDL rats when compared to control animals at weeks 1–4 (control vs BDL: week 1, 482 ± 52 vs 416 ± 70 pM; week 2, 884 ± 188 vs 841 ± 191 pM; week 3, 748 ± 142 vs 620 ± 149 pM; week 4, 498 ± 95 vs 671 ± 105 pM; n = 6 in each group, P = NS for each week).

**mRNA expression and protein amount of ENaC**

Expression of α, β and γENaC mRNAs in the kidneys of BDL rats did not change throughout the 4 week study period (results not shown). Abundance of α, β and γENaC protein was decreased in BDL rats at week 1 (control vs BDL: α, −24 ± 11%; β, −42 ± 9%; and γ, −52 ± 12%; n = 6; P < 0.001); this decrease was more dramatic in BDL controls and BDL vs week 3, P = NS; week 4, P < 0.003.

| Table 1. Body weight of control and BDL rats at weeks 0–4 before and after bile duct excisions |
|-------------------|-----------------|-----------------|-----------------|-----------------|
| Body weight      | Week 0          | Week 1          | Week 2          | Week 3          | Week 4          |
| Control          | 221 ± 9         | 238 ± 9         | 243 ± 9         | 254 ± 13        | 259 ± 11        |
| BDL              | 223 ± 9         | 234 ± 7         | 249 ± 5         | 252 ± 11        | 269 ± 14        |

Control vs BDL: weeks 0-3, P = NS; week 4, P < 0.003.
pronounced at week 2 (control vs BDL: $\alpha$, $-46 \pm 42\%$; $\beta$, $-81 \pm 13\%$; and $\gamma$, $-63 \pm 18\%$; $n=6$; $P<0.001$) and at week 4 (control vs BDL: $\alpha$, $-51 \pm 20\%$; $\beta$, $-73 \pm 18\%$; and $\gamma$, $-55 \pm 20\%$; $n=6$; $P<0.001$) (Figure 1). ANOVA analysis for $\alpha$ENaC protein revealed no difference between the BDL groups at different time points, for $\beta$ENaC BDL the group from week 2 was different when compared to week 1 ($F=9.814$; $P<0.0035$), but not different to BDL at week 4. For $\gamma$ENaC, BDL of week 3 is more decreased compared to week 1 ($F=9.705$; $P<0.004$).

**Table 2.** Urinary $\text{Na}^+$ and $\text{K}^+$ excretion (mmol/24h) and creatinine clearance (ml/min per 100g body wt) before and after bile duct excision

<table>
<thead>
<tr>
<th>Values</th>
<th>Control</th>
<th>BDL</th>
<th>Control</th>
<th>BDL</th>
<th>Control</th>
<th>BDL</th>
<th>Control</th>
<th>BDL</th>
<th>Control</th>
<th>BDL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Week 0</td>
<td>Week 1</td>
<td>Week 2</td>
<td>Week 3</td>
<td>Week 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\text{Na}^+$ urine</td>
<td>$0.78 \pm 0.5$</td>
<td>$0.45^* \pm 0.5$</td>
<td>$0.62 \pm 0.4$</td>
<td>$0.63 \pm 0.9$</td>
<td>$0.40^* \pm 0.6$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\text{K}^+$ urine</td>
<td>$0.19 \pm 0.3$</td>
<td>$0.15 \pm 0.1$</td>
<td>$0.25 \pm 0.6$</td>
<td>$0.14 \pm 0.2$</td>
<td>$0.21 \pm 0.2$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>$0.83 \pm 0.1$</td>
<td>$0.5^** \pm 0.4$</td>
<td>$0.6 \pm 0.3$</td>
<td>$0.5 \pm 0.7$</td>
<td>$0.8 \pm 0.3$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fig. 1.** Protein amount of ENaC subunits in kidneys from rats with BDL-induced liver cirrhosis (black bars) and control animals (open bars) as assessed by quantitative western blot. For each time point, $n=6$ BDL rats were compared with $n=6$ sham-operated animals. Values are mean±SD; $^*P<0.005$ and $^**P<0.01$.

Steady state levels of Sgk1 mRNA were not different in BDL rats and in sham operated animals (results not shown). Nedd4-2 protein content decreased during the study period with the most prominent decline at week 2 (control vs BDL: $-65 \pm 22\%$, $n=6$; $P<0.001$) (Figure 2). The abundance of NCC was significantly increased in BDL compared to control at week 1 (control vs BDL: $+66 \pm 41\%$, $n=6$; $P<0.05$) and
decreased in BDL at week 3 when compared to control (control vs BDL: −85% ± 20%, n = 6; P < 0.0005; Figure 3), without changes in mRNA expression except an increase at week 4. No difference was detected between BDL and control at weeks 2 and 4. ANOVA analysis revealed a difference between BDL week 1 to week 2 (F = 9.934; P < 0.003) and between week 1 and weeks 3 and 4, respectively (F = 9.705; P < 0.004).

**Immunohistochemistry of ENaC and NCC**

The cellular and subcellular localization of α, β and γENaC subunits and NCC were analysed in the kidney cortex of sham operated and BDL rats at week 1 and at week 2 after surgery (four rats in each group). The time point after surgery had no effect on the immunostaining for ENaC subunits. Therefore, results are shown only for week 2 (Figures 4–6). In sham operated rats, the antibody binding pattern for α, β and γENaC subunits and NCC were comparable to those described previously in normal rats. As shown exemplarily for βENaC in Figure 4, ENaC was detectable in CNT and CCD profiles grouped around the cortical radial vessels or running in the medullary rays, respectively. The analysis of the renal tissue obtained from sham operated and BDL revealed similar ENaC distribution. However, βENaC and γENaC (not shown) immunostaining in the CCDs, but not CNTs, were weaker in BDL than in sham operated rats. Higher magnification of the CNT and CCD profiles (Figures 5 and 6) reveal for all groups a predominant intracellular localization of ENaC subunits in the CNT and CCD cells. Only for αENaC was occasionally a weak apical immunostaining observed in some CNT profiles (Figure 5). NCC was detected in DCT profiles located in the renal cortex of sham operated and BDL rats. Consistent with the western blot data, NCC-related immunostaining was more pronounced in DCTs of BDL than of sham operated rats at week 1, but not at week 2 (Figure 7).

**Discussion**

Ascites and oedema formation in liver cirrhosis induced by BDL in rats is due to increased renal sodium reabsorption. The present study was designed to investigate ENaC, the ENaC regulatory proteins Sgk1 and Nedd4-2, and NCC in BDL rats. Following BDL, (i) mRNA of ENaC subunits remain stable, (ii) protein amounts of α, β and γENaC decreases, (iii) mRNA of Sgk1 is unchanged, (iv) subcellular distribution of ENaC subunits is not altered when analysed by immunohistochemistry despite decreased expression of Nedd4-2 protein, and (v) protein abundance of NCC increases at week 1 when analysed by immunoblotting and immunohistochemistry.

The protein amount of α, β and γENaC was decreased in BDL rats despite stable mRNA expression of the corresponding ENaC subunits (Figure 1).
Thus, it is not possible to link directly the amount of ENaC protein with transcription. Berger et al. [14] studied the relevance of the MR on mRNA abundance of ENaC by using MR knockout mice. MR deficiency did not affect the mRNA abundance of α, β and γENaC subunits in the kidney of MR−/−mice, indicating that MR-mediated control of renal Na⁺ reabsorption was not achieved by transcriptional control of ENaC expression [14]. Recent investigations by Escoubet et al. [15] revealed that aldosterone depletion had no or only a weak effect on renal α, β and γENaC subunits mRNA expression. Our results of decreased amounts of α, β and γENaC despite enhanced MR activation by 11b-hydroxy-steroids in BDL rats are in line with these observations suggesting the absence of a direct link between MR activation and mRNA and protein levels of ENaC subunits. Thus, other as yet unidentified mechanisms are involved in the regulation of α, β and γENaC in health and disease states [14,15].

We measured the total amount of ENaC protein by quantitative western blot. It is conceivable that the pattern of intracellular distribution of ENaC subunits is altered in the BDL-induced disease state, an effect that would have been missed by these analyses. An altered pattern of ENaC distribution might be attributable to a post-transcriptional regulatory event, either by affecting biosynthesis or stability of the ENaC proteins.

Two proteins are interesting with respect to the regulation of ENaC: Nedd4-2, which negatively controls cell surface density of ENaC, and Sgk1, which is an aldosterone-dependent, positive regulator of ENaC expression [7,16]. Nedd4-2 protein amount was decreased in weeks 1–4 in BDL rats when compared to sham operated animals (Figure 2). Based on the role of Nedd4-2, one might predict an increased abundance of ENaC protein in rats with BDL, which is definitely not the case (Figure 1). In the present study we assessed the total amount of Nedd4-2. Thus it is still conceivable that the amount of biologically active
unphosphorylated Nedd4-2 was unchanged in BDL rats and therefore ENaC did not change. Alternatively, Nedd4-2 might have changed in kidney segments not expressing ENaC, thus concealing a direct link between Nedd4-2 and ENaC levels. Nedd4-2 simply affects intracellular localization of ENaC and not the total pool. To assess the effect of the observed downregulation of Nedd4-2 on the intracellular localization of ENaC, we performed an immunohistochemical analysis of all three ENaC subunits. Subcellular distribution of all three subunits was not disturbed in BDL animals when compared to the appropriate controls, indicating that Nedd4-2 downregulation appears to exhibit no or only a minor effect on intracellular localization of ENaC in this specific disease state (Figures 4–6). An unexplained finding is the slight, but steadily decreasing protein abundance of Nedd4-2 in the controls (Figure 2). mRNA of Sgk1 is present in BDL rats; however, no modulation of Sgk1 expression assessed by steady-state mRNA measurements was observed.

We measured α, β and γENaC mRNA and protein in BDL rats but did not assess ENaC activity in the CCD. One might speculate that ENaC is activated despite the presence of normal or low amounts of ENaC proteins. Such an activation might occur through increased bile acid concentrations in BDL...
rats. Lima et al. [17] have shown that the bile acid deoxycholate stimulates the amiloride sensitive sodium current in frog skin. However, until the activity of ENaC is not measured directly by electrophysiological methods in the renal tubular segments from BDL rats such a mechanism remains speculative.

Jonassen et al. [18] proposed the thick ascending limb (TAL) and not the CCD to be responsible for abnormal renal sodium retention in BDL rats. They measured Na,K-ATPase activity at V_{max} conditions in microdissected tubules from TAL and outer medullary collecting duct (OMCD) in rats 5 weeks after BDL. Na,K-ATPase activity per mm tubule length was decreased in the OMCD and unchanged in the TAL. This interesting finding is not at variance with our study because the authors considered the OMCD and not CCD and, furthermore, the measurements took place at a relatively late time point after BDL (week 5) when the mineralocorticoid escape phenomenon is present. In addition, it has been suggested that measurement of Na,K-ATPase at V_{max} and not at lower V might jeopardize the identification of dysregulations of the Na,K-ATPase activity in disease states.

The NCC located in the apical membrane of the DCT is responsible for the thiazide-sensitive sodium uptake. Expression of NCC was increased 1 week after BDL with stronger immunostaining for NCC in the DCTs when compared to control (Figures 3 and 7). NCC mediated sodium uptake is stimulated by forskolin, a drug that promotes the adenyl cyclase-catalyzed production of cAMP, acting through PKA. However, PKA-induced sodium uptake by activation of NCC does not increase expression of NCC and therefore might not account for the mechanism of increased NCC in BDL rats. In the long term, aldosterone causes a significant increase in protein amount of NCC and in NCC mediated sodium uptake. This mechanism seems unlikely because the plasma aldosterone concentration was similar in BDL animals when compared to the control animals. An aldosterone-independent activation of MR has been identified in rats with BDL and in human subjects with elevated serum bile acids might represent a possible pathway to activate NCC in the cirrhotic disease state.

An unexplained finding is the strong decrease in NCC protein amount 3 weeks after BDL. A similar observation was reported by Fernandez-Llama et al. [19] in a model of liver cirrhosis secondary to chronic CCl_{4} inhalation. The authors measured a decrease in renal NCC protein at weeks 12–25 after starting cirrhosis induction with CCl_{4}. One might speculate if this decreased NCC protein amount in BDL rats at 3 weeks and in the chronic cirrhosis model induced by CCl_{4} inhalation is not simply representing a mineralocorticoid escape phenomenon known to decrease substantially the NCC protein amount in the kidney [19]. In a recent publication from Fernandez-Llama et al. an increase in NCC protein and zENaC was observed in the same liver cirrhosis model induced by CCl_{4} inhalation. The authors relate these changes to an aldosterone effect. The discrepancy of the different observations is probably related to the different time point of observation, and with regard to our study, to the different animal model [20].

In conclusion, the expression of NCC is increased in kidney homogenates 1 week after BDL, a finding that might explain early renal sodium retention in BDL induced liver disease. The expression of \alpha, \beta and \gamma ENaC subunits is decreased in kidney tissue of BDL rats without evidence for changes in subcellular distribution of the three ENaC subunits.

Acknowledgements. We thank L. Dijkink for \alpha ENaC antibody, Nicolette Fareman for \gamma ENaC antibody, Olivier Staub for Nedd4-2 antibody, Bernard Rosser for \alpha, \beta and \gamma antibodies, and Beatrice Rohrbach for technical assistance. This work was supported by two grants from the Swiss National Foundation for Scientific Research (Nr 32-57205.99).

Conflict of interest statement. None declared.

References

12. Kamynina E, Tauxe C, Staub O. Distinct characteristics of two human Nedd4 proteins with respect to epithelial Na(+)


Received for publication: 28.7.04
Accepted in revised form: 22.4.05